Ab­b­Vie dives deep­er in­to eye care, pay­ing $370M cash — with a $1.4B sweet­en­er — to part­ner on VEGF gene ther­a­py

Ab­b­Vie is ex­pand­ing the oph­thal­mol­o­gy seg­ment of their pipeline to­day, bag­ging a gene ther­a­py now in piv­otal tri­als for wet age-re­lat­ed mac­u­lar de­gen­er­a­tion for a …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER